Literature DB >> 9001435

Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)

S H Kroft, M S Tallman, J M Shaw, M Thangavelu, L C Peterson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9001435     DOI： 10.1038/sj.leu.2400523

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

Review 1.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.

Authors:  Peter McLaughlin; Elihu Estey; Armand Glassman; Jorge Romaguera; Felipe Samaniego; Ana Ayala; Kimberly Hayes; Anne Marie Maddox; H Alejandro Preti; Fredrick B Hagemeister
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

4.  Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis.

Authors:  Daisuke Suzuki; Ryoji Kobayashi; Hirozumi Sano; Kenji Kishimoto; Kazue Yasuda; Masanori Nakanishi; Tetsuro Nagashima; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

Review 5.  Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

Authors:  Tadeusz Robak; Anna Korycka; Ewa Lech-Maranda; Pawel Robak
Journal:  Molecules       Date:  2009-03-23       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.